aging hepatitis virus hcv -infected persons united states multiple cohort model hcv prevalence disease progression pubmed ncbi abstract background aims prevalence chronic hepatitis ch-c remains high complications infection common goal project future prevalence ch-c complications methods developed multicohort natural history model overcome limitations previous models predicting disease outcomes benefits therapy results prevalence ch-c peaked num num million fibrosis progression inversely related age infection cirrhosis complications common age num years infection occurred proportion ch-c cirrhosis projected reach num num num num total number cirrhosis peak num million num higher current level num decline hepatic decompensation liver cancer continue increase num num years treatment infected patients num reduce risk cirrhosis decompensation cancer liver-related deaths num num num num current response rates antiviral therapy conclusions prevalence hepatitis cirrhosis complications continue increase decade affect older num years age current treatment patterns effect complications wider application antiviral treatment responses agents significantly reduce impact disease coming years 
